Introduction {#S0001}
============

Endocrine tumors are characterized by a common phenotype general markers (i.e., neuron-specific enolase, chromogranin, synaptophysin) and hormonal secretion products. Primitive hepatic localization is very rare, representing less than 0.3% of all endocrine tumors of the digestive system with a female predominance; the sex ratio is 1.6 / 1, with an average age of 51 \[[@CIT0001], [@CIT0002]\].

Patient and observation {#S0002}
=======================

We report a case of primary hepatic neuroendocrine carcinoma (PHNEC) admitted in our departement. A 53 years old patient, known diabetic, admitted for epigastric pain combined with diarrhea, abdominal distension and flush syndrome. This evolved in a deterioration of general condition. The clinical exam attested a facial reddening, hepatomegaly. An abdominal ultrasound showed a giant hepatic hemangioma of the posterior segment. A thoraco-abdominal-pelvic CT objective tumor lesion localized segment VI and VII of the liver with ascites ([Figure 1](#F0001){ref-type="fig"}).

![CT scan image of a PHNEC patient; CT scan showing a liver mass (segment VI and VII)](PAMJ-20-254-g001){#F0001}

Digestive endoscopy was performed for the patient and no Neoplasm was found in the stomach, duodenum, colon, or rectum. Capsule endoscopy for the small intestine was normal. Serum 5-HT, chromogranin A (CgA), and urinary 5-hydroxyindoleacetic acid (5-HIAA) examinations were very high with values of 225 ng/ml and 19 mg/24h successively. CT scan of the thorax was normal. The patient were Alpha Fetoprotein (AFP-), Carcinoembryonic antigen (CEA -) and Carcinoma Antigen (CA19-9-).

A liver biopsy with immunohistochemical study confirmed the diagnosis of primary neuroendocrine carcinoma ([Figure 2](#F0002){ref-type="fig"}, [Figure 3](#F0003){ref-type="fig"}, [Figure 4](#F0004){ref-type="fig"}). The patient has received chemotherapy with Cisplatin 100 mg/m2/day J1 and Etoposide 100 mg/m2/day J1 to J3 for 6 months, with good clinical and radiological improvement, and then he undergone 6 months more treatments: 12 months of treatments in total. After 18 months of follow up, the patient is in complete remission and we opted for a clinical and radiological monitoring.

![Microscopic image at low magnification showing tumor proliferation](PAMJ-20-254-g002){#F0002}

![Hematoxylin eosin staining](PAMJ-20-254-g003){#F0003}

![Immunohistochemistry, chromogranin A](PAMJ-20-254-g004){#F0004}

Discussion {#S0003}
==========

Primary hepatic neuroendocrine carcinoma is rare \[[@CIT0001], [@CIT0002]\], clincal symptoms are not specific, and imaging is fundamental to guide diagnosis. Serum 5-HT or hydroxyindoleacetic acid (5-HIAA) 24 h urine levels may be effective markers with sensitivity of 73% and a specificity of more than 90%. Serum (CGA) is a sensitive marker in the diagnosis with a sensitivity of 87-100% and a specificity of 92%, but diagnosis confirmation is the histoligical examination after biopsy or surgery \[[@CIT0003]\].

It is difficult to differentiate PHNEC from other solid tumors, especially hepatocellular carcinoma or hepatic metastasis of other tumor; therefore, postoperative pathologic examination is the main method for a final diagnosis \[[@CIT0001], [@CIT0004]\]. Treatment includes several methods, surgery, systemic chemotherapy and transcatheter arterial chemoembo-lization \[[@CIT0005], [@CIT0006]\]. Prognosis depends on the initial stage of the disease. Research indicated that the recurrence rate at 5 years was 18% and the survival rate at 5 years was 74% -78% \[[@CIT0007]\].

Conclusion {#S0004}
==========

Primary hepatic neuroendocrine carcinoma remains a rare diagnosis, requiring careful biological, endoscopic, radiological and histological examinations to eliminate the secondary localization of extrahepatic tumor.
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